TyrosIne Kinase Inhibitors in Chronic Myeloid Leukemia: Efficacy and Tolerability. The TIKlet Study

CompletedOBSERVATIONAL

Enrollment

412

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions

Chronic Myeloid Leukemia

Interventions

DRUG

Imatinib/Nilotinib

Imatinib: 400 mg/day oral - Nilotinib: 600-800 mg/day oral

Trial Locations (2)

Division of Hematology and Transplants, University of Siena, Siena

Unit of Hematology, Azienda Ospedaliero Universitaria Pisana, Pisa

All Listed Sponsors

lead

University of Pisa

OTHER

NCT01860456 - TyrosIne Kinase Inhibitors in Chronic Myeloid Leukemia: Efficacy and Tolerability. The TIKlet Study | Biotech Hunter | Biotech Hunter